Cardiol Therapeutics Class Stock Analysis

Cardiol Stock Analysis Notes

The company recorded a loss per share of 0.54. Cardiol Therapeutics had not issued any dividends in recent years. Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company was incorporated in 2017 and is headquartered in Oakville, Canada. CARDIOL THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 6 people. For more info on Cardiol Therapeutics Class please contact MBA MBA at 289-910-0850 or go to https://www.cardiolrx.com.

Cardiol Therapeutics Investment Alerts

Cardiol Largest EPS Surprises

View All Earnings Estimates

Cardiol Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 188.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cardiol Therapeutics's market, we take the total number of its shares issued and multiply it by Cardiol Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Cardiol Profitablity

Management Efficiency

Cardiol Therapeutics has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0844) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -1.1. At this time, Cardiol Therapeutics' Total Assets are very stable compared to the past year. As of the 29th of November 2024, Non Current Assets Total is likely to grow to about 610.6 K, while Net Tangible Assets are likely to drop about 32.7 M.

Technical Drivers

As of the 29th of November, Cardiol Therapeutics shows the Standard Deviation of 3.83, risk adjusted performance of (0.01), and Mean Deviation of 2.85. Cardiol Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cardiol Therapeutics Price Movement Analysis

Cardiol Therapeutics Outstanding Bonds

Cardiol Therapeutics Predictive Daily Indicators

Cardiol Therapeutics Forecast Models

Cardiol Therapeutics' time-series forecasting models are one of many Cardiol Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiol Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cardiol Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cardiol shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cardiol Therapeutics. By using and applying Cardiol Stock analysis, traders can create a robust methodology for identifying Cardiol entry and exit points for their positions.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.